PREVENTION OF GASTROINTESTINAL COMPLICATIONS IN THE TREATMENT OF PATIENTS WITH CARDIAC PROFILE
Abstract
It is well known that in the structure of total mortality in Russia more than 57 % are cardiovascular disease (CVD). From the point of view of pathophysiology the basis of premature cardiovascular death in almost half the cases lies with atherothrombosis: the situation when the tyre is destroyed atherosclerotic plaque is formed thrombus, covering partially or totally the lumen of the vessel, and depending on the location of the lesion, the patient develops a myocardial infarction, ischemic atherothrombotic stroke, or gangrene of the lower extremities. Since the completion of the famous Framingham study, the notion of “risk factor” and therefore the concept of secondary and primary prevention of CVD. Among the drugs that have the ability to reduce CVD risk include antiplatelet agents and statins. It was during the administration of these drugs in some cases can cause serious problems.
About the Authors
G. A. Baryshnikova
Central state medical Academy” of Department for presidential Affairs of RF
Russian Federation
Russian Federation
S. A. Chorbinskaya
Central state medical Academy” of Department for presidential Affairs of RF
Russian Federation
Russian Federation
N. A. Kudryavtseva
Central state medical Academy” of Department for presidential Affairs of RF
Russian Federation
Russian Federation
References
1. Francis K. L. et. al. Clopidogrel versus Aspirin and Esomeprazole to Prevent Recurrent Ulcer Bleeding. N Engl J Med. 2005; 352:238-44.
2. Kreutz RP, Stanek EJ, Aubert R et al. Impact of proton pump inhibitors on the effectiveness of clopidogrel after coronary stent placement: the clopidogrel Medco outcomes study. Pharmacotherapy. 2010 Aug;30(8):787-796.
3. Бордин Д. С. Что следует учитывать при выборе ингибитора протонной помпы больному ГЭРБ? // Медицинский альманах. 2010. № 1(10) март. - С. 127-130.
4. Angiolillo DJ, Gibson CM, Cheng S et al. Differential effects of omeprazole and pantoprazole on the pharmacodynamics and pharmacokinetics of clopidogrel in healthy subjects: randomized, placebo-controlled, crossover comparison studies. Clin Pharmacol Ther. 2011 Jan;89(1):65-74.
5. Национальные рекомендации по антитромботической терапии у больных со стабильными проявлениями атеротромбоза. Кардиоваскулярная терапия и профилактика. 2009; 8(6), Приложение 6.
6. Braunwald E, Antman EM, Beasley JW et al. ACC/AHA guideline update for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction-2002: Summary article: A report of the American College of Cardiology. American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients With Unstable Angina). Circulation. 2002; 106: 1893-1900.
7. Angiolillo DJ, Gibson CM, Cheng S et al. Differential effects of omeprazole and pantoprazole on the pharmacodynamics and pharmacokinetics of clopidogrel in healthy subjects: randomized, placebo-controlled, crossover comparison studies. Clin Pharmacol Ther. 2011 Jan;89(1):65-74.
8. Ferreiro JL, Ueno M, Tomasello SD et al. Pharmacodynamic evaluation of pantoprazole therapy on clopidogrel effects: results of a prospective, randomized, crossover study. Circ Cardiovasc Interv. 2011 Jun;4(3):273-279.
9. Braunwald E, Antman EM, Beasley JW et al. ACC/AHA guideline update for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction-2002: Summary article: A report of the American College of Cardiology. American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients With Unstable Angina). Circulation. 2002; 106: 1893-1900.
10. Angiolillo DJ, Gibson CM, Cheng S et al. Differential effects of omeprazole and pantoprazole on the pharmacodynamics and pharmacokinetics of clopidogrel in healthy subjects: randomized, placebo-controlled, crossover comparison studies. Clin Pharmacol Ther. 2011 Jan; 89(1):65-74.
11. Fujimori S., Takahashi Y., Gudis K. Rebamipide has the potential to reduce the intensity of NSAID-induced small intestinal injury: a dou ble-blind, randomized, controlled trial evaluated by capsule endoscopy. J. Gastroenterol. 2011; 46 (1): 57-64.
12. Tozawa K., Oshima T., Okugawa T. et al. Does Rebamipide Prevent Gastric Mucosal Injury in Patients Taking Aspirin and Clopidogrel? Dig. Dis. Sci. 2014. 59: 1671-1673.
13. Naito Y, Yoshikawa T. Rebamipide: a gastrointestinal protective drug with pleiotropic activities. Expert Rev Gastroenterol Hepatol. 2010; 4 (3): 261-270.
14. Mizukami K., Murakami K., Abe T. et al. Aspirin-induced small bowel injuries and the preventive effect of rebamipide. World. J. Gastroenterol. 2011; 17 (46): 5117-5122.
15. Fujimori S., Takahashi Y., Gudis K. Rebamipide has the potential to reduce the intensity of NSAID-induced small intestinal injury: a dou ble-blind, randomized, controlled trial evaluated by capsule endoscopy. J. Gastroenterol. 2011; 46 (1): 57-64.
16. Mitsuki Miyata, Toshihiro Konagaya, Shiniti Kakumu, Takeshi Mori. Successful treatment of severe pouchitis with rebamipide refractory to antibiotics and corticosteroids: A case report. World J Gastroenterol. 2006; 12 (4): 656-658.
17. Maron DJ, Fazio S., Linton MF. Современные перспективы применения статинов. Международный Медицинский Журнал. - 2000 год. - № 6.
18. Корнеева О. Н., Драпкина О. М., Буеверов А. О., Ивашкин В. Т. Неалкогольная жировая болезнь печени как проявление метаболического синдрома. Клинические перспективы гастроэнтерологии, гепатологии. 2005. № 4.
19. Ивашкин В. Т., Драпкина О. М., Шульпекова Ю. О. Диагностика и лечение неалкогольной жировой болезни печени. Рос. мед. вести. 2009. Т. XIV. № 3.
20. Драпкина О. М., Смирин В. И., Ивашкин В. Т. Неалкогольная жировая болезнь печени - современный взгляд на проблему. Лечащий врач. 2010. № 5.
21. Dima A., Marinescu A. G., Dima A. C. Non-alcoholic Fatty Liver Disease and the Statins Treatment. Rom. J. Intern. Med. 2012. Vol. 50, 1. P. 19-25.
22. Kivici M, Gulten M, Gurel S, Nak SG, Dolar E, Savci G, et al. Ursodeoxycholic acid and atorvastatin in the treatment of nonalcoholic steatohepatitis. Can J Gastroenterol. 2003,17:13-18.
23. Chalasani N., Aljadhey H., Kesterson J. Patients with elevated liver enzymes are not at higher risk for statin hepatotoxicity. Gastroenterology. 2004;126:1287-1292.
24. Athyros V. G., Tziomalos K., Gossios T. D. et al. Safety and efficacy of long-term statin treatment for cardiovascular events in patients with coronary heart disease and abnormal liver tests in the Greek Atorvastatin and Coronary Heart Disease Evaluation (GREACE) Study: a post-hoc analysis // Lancet. 2010. Vol. 376. P. 1916-1922.
25. Драпкина О. М., Дуболазова Ю. В. Статины и печень: тупик или новые горизонты? РМЖ. Человек и лекарство. 2009. № 4.
26. Argo C. K., Loria P., Caldwell S. H., Lonardo A. Statins in liver disease: a molehill, an iceberg, or neither? Hepatology. 2008 Aug;48(2):662-669.
27. Habeos I. G., Ziros P. G., Chartoumpekis D. et al. Simvastatin activates Keap1/Nrf2 signaling in rat liver. J Mol Med. 2008 Sep 2. [Epub ahead of print].
28. Dongiovanni P., Petta S., Mannisto V. et al. Statin use and non-alcoholic steatohepatitis in at risk individuals. J Hepatol. 2015; 63: 705-712.
29. Драпкина О. М., Фадеева М. В. Статины и печень. Коротко о главном. РМЖ, 2014, № 6. С. 428.
30. Напалков Д. А. Безопасность статинов: что нужно знать практикующему врачу? Рациональная Фармакотерапия в Кардиологии 2014;10(3) 331-335.
31. Gastroenterology: manual / ed. by F. I. Komarov, S. I. Rapoport. - M.: Medical informational agency, 2010. 864.
32. Довженко, Л. И. Пациент с ишемической болезнью сердца и хроническим стеатогепатитом: как проводить гиполипидемическую терапию. Укр. мед. часопис. - 2007. -№ 1. - С. 1-4.
33. Диагностика и лечение диффузных заболеваний печени / под ред. В. Т. Ивашкина, Н. Д. Ющука. - М., 2003. - 22 с.
34. Рекомендации экспертов Всероссийского научного общества кардиологов по диагностике и лечению метаболического синдрома / под ред. И. Е. Чазовой. - М., 2009. - 32 с.
Review
For citations:
Baryshnikova G.A., Chorbinskaya S.A., Kudryavtseva N.A. PREVENTION OF GASTROINTESTINAL COMPLICATIONS IN THE TREATMENT OF PATIENTS WITH CARDIAC PROFILE. Experimental and Clinical Gastroenterology. 2017;(6):120-125. (In Russ.)
Views:
202
Email this article 